Ira Zackon, MD

Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.

Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.

Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.